logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Prefilled Syringes Market, By Type (Bare Metal, Drug Eluting, BVS), By Application (Rheumatoid Arthritis, Anaphylaxis, Diabetes, Others) By End User (Mail Order Pharmacies, Hospitals, Ambulatory Surgery Center) opportunities and forecast 2020-2027

  • DLR2182
  • 19 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Fast-paced growth of the feature-rich devices with the underlying technical advancements allowing convenient and safer self-injections is anticipated to fuel market growth over the forecast period. Prefilled syringes help the healthcare practitioners in saving efforts and time while preparing the injection doses. Additionally, they help decrease the device-based and manual measuring errors and waste of active pharmacological ingredients while shifting solutions from vials to the syringe.
Advancement in the biopharmaceutical industry has direct positive impact on demand for the prefilled syringes as they aid minimize loss of potency though transferring biopharmaceuticals in the different containers. Some of biological drugs that are packed in prefilled syringes which include small, as well as large, particles such as monoclonal antibodies and antibody drug conjugates.

On the other hand, controlled production of the plastic syringes is challenging market growth. Contrary effects of the plastic products on environment are also restraining adoption of these devices. Though, major companies in field are trying to innovate advanced materials that can be recyclable, disposable, and appropriate for containing these injectable drugs. This factor is expected to augment market growth in near future.

Segment Overview

The disposable segment led global market in 2019 and is estimated to remain dominant through forecast years owed to its varied applications. High inclination for patient safety has caused increased usage of the disposable devices in the homecare and hospitals settings. Moreover, the devices decrease contamination risks, which is projected to boost the demand.

However, reusable segment is anticipated to register fastest growth rate throughout the forecast period. Expansion of advanced auto-injectors, including VigiPen by VigiHealth, and i-Pen by Haselmeier AG has increased the segment growth.

Regional Overview

Europe is presently dominating global market owing to the growing demand for the prefilled syringes in region. Moreover, robust presence of the major market players including Schott Group, Gerresheimer AG, and Owen Mumford Ltd. is further likely to help increase the region’s growth.

The European Board of Anesthesiology (EBA) recommends use of the prefilled syringes for anaesthesia. Growing number of the surgeries due to numerous factors and the faster approval processes by numerous regulatory authorities are factors predictable to drive Europe regional market.

The Asia Pacific market is anticipated to grow at lucrative CAGR during forecast period. Rapidly emerging economies, such as China and India, and availability of the untapped growth prospects are key factors fuelling the region’s expansion. Furthermore, large patient population and the growing prevalence of numerous chronic diseases are anticipated to fuel sector growth in the region.

Competitor overview

Price discrimination approach and public awareness campaigns implemented by the Mylan N.V. for its EpiPen, a patent protected device, an epinephrine injection, is resulting in growth of anaphylaxis application segment.

Prefilled products aid as a great tool for the storage of vaccines and the other biotech drugs, which are mostly unstable and are more prone to change the properties while shifting from vials. Lately U.S. FDA approved the Auvi Q by Kaléo. The device is planned for use in the life-threatening allergic responses in children and infants. Some of key players in global market are Schott Group, Gerresheimer AG, Unilife Corporation, Owen Mumford, Nipro Medical Corporation, and Haselmeier AG. The companies focus on organising investments to rise their manufacturing competences and hence sustain their revenue share.

Key Players
  1. Gerresheimer AG
  2. Schott Group
  3. Unilife Corporation
  4. Nipro Medical Corporation
  5. Owen Mumford
  6. Haselmeier AG

Market Segmentation

By Type
  • Reusable
  • Disposable
By Application
  • Anaphylaxis
  • Diabetes
  • Rheumatoid Arthritis
  • Others
By Distribution Channel
  • Mail Order Pharmacies
  • Hospitals
  • Ambulatory Surgery Centers
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 14

    2 Introduction 16

    • 2.1 Definition 17
    • 2.2 Scope of the Study 17
    • 2.3 Research Objective 17
    • 2.4 Assumptions & Limitations 17
      • 2.4.1 Assumptions 17
      • 2.4.2 Limitations 17
    • 2.5 Market Structure 17

    3 Research Methodology 18

    • 3.1 Primary Research Methodology 19
    • 3.2 Secondary Research Methodology 21
    • 3.3 Market Size Estimation 22
    • 3.4 Forecast Model 22

    4 Market Dynamics 23

    • 4.1 Introduction 24
    • 4.2 Drivers 25
      • 4.2.1 High Prevalence of Chronic Diseases 25
      • 4.2.2 Technological Advancements 25
    • 4.3 Restraints 25
      • 4.3.1 Product Recalls 25
    • 4.4 Challenge 25
      • 4.4.1 Stringent Regulations 25
    • 4.5 Mega Trend 26
      • 4.5.1 Technological Trends 26
    • 4.6 Macroeconomics 26

    5 Market Factor Analysis 27

    • 5.1 Porter’s Five Forces Model 28
      • 5.1.1 Bargaining Power of Suppliers 28
      • 5.1.2 Bargaining Power of Buyers 29
      • 5.1.3 Threat of New Entrants 29
      • 5.1.4 Threat of Substitutes 29
      • 5.1.5 Intensity of Rivalry 29
    • 5.2 Value Chain Analysis 30
      • 5.2.1 R&D 30
      • 5.2.2 Manufacturing 30
      • 5.2.3 Distribution & Sales 30
      • 5.2.4 Post-Sales Monitoring 31
    • 5.3 Demand & Supply: Gap Analysis 31
    • 5.4 Pricing Analysis 31

    6 Global Prefilled Syringes Market, by Material 32

    • 6.1 Introduction 33
    • 6.2 Glass Prefilled Syringes 35
      • 6.2.1 Oil siliconised syringes 35
      • 6.2.2 Baked on silicone syringes 36
    • 6.3 Plastic Syringes 36

    7 Global Prefilled Syringes Market, by Type 37

    • 7.1 Introduction 38
    • 7.2 Conventional Prefilled Syringes 39
    • 7.3 Safety Prefilled Syringes 39

    8 Global Prefilled Syringes Market, by Design 40

    • 8.1 Introduction 41
    • 8.2 Single-chamber Prefilled Syringes 42
    • 8.3 Dual-chamber Prefilled Syringes 42
    • 8.4 Customized Prefilled Syringes 42

    9 Global Prefilled Syringes Market, by End-User 43

    • 9.1 Introduction 44
    • 9.2 Hospitals/Clinics 45
    • 9.3 Ambulatory Surgical Center 45

    10 Global Prefilled Syringes, by Region 46

    • 10.1 Introduction 47
    • 10.2 Europe 48
      • 10.2.1 Western Europe 50
        • 10.2.1.1 Germany 52
        • 10.2.1.2 France 53
        • 10.2.1.3 U.K. 54
        • 10.2.1.4 Italy 56
        • 10.2.1.5 Spain 57
        • 10.2.1.6 Rest of Western Europe 59
      • 10.2.2 Eastern Europe 60
    • 10.3 Americas 62
      • 10.3.1 North America 64
        • 10.3.1.1 U.S. 66
        • 10.3.1.2 Canada 67
      • 10.3.2 South America 68
    • 10.4 Asia Pacific 70
      • 10.4.1 Japan 72
      • 10.4.2 China 73
      • 10.4.3 India 74
      • 10.4.4 Australia 76
      • 10.4.5 Republic of Korea 77
      • 10.4.6 Rest of Asia Pacific 79
    • 10.5 Middle East & Africa 81
      • 10.5.1 Middle East 83
      • 10.5.2 Africa 84

    11 Competitive Landscape 86

    • 11.1 Introduction 87

    12 Company Profiles 88

    • 12.1 Gerresheimer AG 89
      • 12.1.1 Company Overview 89
      • 12.1.2 Financial Overview 89
      • 12.1.3 Products Offering 90
      • 12.1.4 Key Developments 90
      • 12.1.5 SWOT Analysis 90
      • 12.1.6 Key Strategy 90
    • 12.2 Schott AG 91
      • 12.2.1 Company Overview 91
      • 12.2.2 Financial Overview 91
      • 12.2.3 Products Offering 92
      • 12.2.4 Key Developments 92
      • 12.2.5 SWOT Analysis 92
      • 12.2.6 Key Strategy 92
    • 12.3 Medtronic 93
      • 12.3.1 Company Overview 93
      • 12.3.2 Financial Overview 93
      • 12.3.3 Products Offering 94
      • 12.3.4 Key Developments 94
      • 12.3.5 SWOT Analysis 94
      • 12.3.6 Key Strategy 94
    • 12.4 TERUMO CORPORATION 95
      • 12.4.1 Company Overview 95
      • 12.4.2 Financial Overview 95
      • 12.4.3 Products Offering 96
      • 12.4.4 Key Developments 96
      • 12.4.5 SWOT Analysis 96
      • 12.4.6 Key Strategy 96
    • 12.5 Abbott 97
      • 12.5.1 Company Overview 97
      • 12.5.2 Financial Overview 97
      • 12.5.3 Products Offering 97
      • 12.5.4 Key Developments 98
      • 12.5.5 SWOT Analysis 98
      • 12.5.6 Key Strategy 98
    • 12.6 Nipro Corporation 99
      • 12.6.1 Company Overview 99
      • 12.6.2 Financial Overview 99
      • 12.6.3 Products Offering 100
      • 12.6.4 Key Developments 100
      • 12.6.5 SWOT Analysis 100
      • 12.6.6 Key Strategy 100
    • 12.7 Baxter 101
      • 12.7.1 Company Overview 101
      • 12.7.2 Financial Overview 101
      • 12.7.3 Products Offering 102
      • 12.7.4 Key Developments 102
      • 12.7.5 SWOT Analysis 102
      • 12.7.6 Key Strategy 102
    • 12.8 Becton, Dickinson and Company 103
      • 12.8.1 Company Overview 103
      • 12.8.2 Financial Overview 103
      • 12.8.3 Products Offering 104
      • 12.8.4 Key Developments 104
      • 12.8.5 SWOT Analysis 104
      • 12.8.6 Key Strategy 104
    • 12.9 West Pharmaceutical 105
      • 12.9.1 Company Overview 105
      • 12.9.2 Financial Overview 105
      • 12.9.3 Products Offering 106
      • 12.9.4 Key Developments 106
      • 12.9.5 SWOT Analysis 106
      • 12.9.6 Key Strategy 106
    • 12.10 Weigao Group 107
      • 12.10.1 Company Overview 107
      • 12.10.2 Financial Overview 107
      • 12.10.3 Products Offering 108
      • 12.10.4 Key Developments 108
      • 12.10.5 SWOT Analysis 108
      • 12.10.6 Key Strategy 108
    • 12.11 Vetter Pharma International GmbH 109
      • 12.11.1 Company Overview 109
      • 12.11.2 Financial Overview 109
      • 12.11.3 Products Offering 109
      • 12.11.4 Key Developments 109
      • 12.11.5 SWOT Analysis 109
      • 12.11.6 Key Strategy 110
    • 12.12 OMPI (A Stevanato Group Company) 111
      • 12.12.1 Company Overview 111
      • 12.12.2 Financial Overview 111
      • 12.12.3 Products Offering 111
      • 12.12.4 Key Developments 111
      • 12.12.5 SWOT Analysis 111
      • 12.12.6 Key Strategy 111

    13 Conclusion 112

    • 13.1 Key Findings 113
      • 13.1.1 CEO’s Viewpoint 113
      • 13.1.2 Unmet Needs 113
      • 13.1.3 Key Companies to Watch 113
      • 13.1.4 Prediction of the Prefilled Syringes Industry 113

    14 Appendix 114

    • 14.1 Discussion Blue Print 115
    • 14.2 Recent key developments 116
    • 14.3 References 116

    Report You Might be Interested